ClinicalTrials.gg
RecruitingNCT04082767Updated Dec 11, 2023

Sedation Efficacy of Dexmedetomidine Versus Midazolam in Critically Ill Ventilated Children

A Phase 3 interventional study of Precedex and Midazolam in Mechanically Ventilated, Critically Ill Children, sponsored by Douglas Fraser. Recruiting at 1 site in Canada. Open to participants aged 1 Month to 17 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by Douglas Fraser · Phase 3, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Sep 2024, 2 years 2 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
1 Month to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 78 studies testing dexmedetomidine in Delirium — 14 open to participants now, 17 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Planned enrollment
35th of 78
120 · median 98
Started
2021
with 6 others
Phase 3
11 of 78
3 open now
Primary completion
2024-09
later than 0 of 16 live
Registered
45th of 78
by date

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 35th largest by planned enrollment, is one of 7 that started in 2021, is one of 11 in phase 3, reaches primary completion later than 0 of the 16 other live ones, and was the 45th registered.

Delirium

935 studies on the registry are indexed under Delirium; 188 are open to participants now.

Browse Delirium studies →

Open to participants now

14 of the 78 studies testing dexmedetomidine in Delirium are open now, in 5 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 124 Delirium studies recruiting now, 96 (77%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 14 take healthy volunteers.

This study: 1 Month to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

There is a significant lack of adequately powered randomized clinical trial (RCT) data to determine the comparative safety and effectiveness of sedative treatments in pediatric patients. In many centres the standard of care for sedation in pediatric critical care unit (PCCU) patients includes the use of benzodiazepines despite the known negative effects of increased patient agitation and delirium, which can contribute to longer PCCU and hospital length of stay (LOS). The use of an alternative sedative, dexmedetomidine may reduce negative effects in this population. As such, the investigators plan to conduct a well designed comparative RCT to determine the most effective and safest sedative in this vulnerable population utilizing clinical assessments of sedation levels and delirium instance, electroencephalography (EEG) analysis and patient important outcomes.

03

Conditions studied

  • Mechanically Ventilated, Critically Ill Children

Browse trials for

Keywords

  • sedation, delirium, pediatric, critical care
04

Who can participate

Ages eligible
1 Month to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age is 1 month to 18 years inclusive
  2. The patient is intubated and is expected to remain intubated for at least the next 48 hours
  3. The patient has not been receiving mechanical ventilation for more than 72 hours
  4. The patient must already be receiving an opioid infusion per PCCU Guidelines for Sedation \& Analgesia for Procedures Outside O.R. and need additional sedation.

Exclusion criteria

Exclusion Criteria:

  1. Admission is a consequence of suspected or proven drug overdose
  2. Patient is receiving dialysis
  3. Known pregnancy or lactation
  4. Neuromuscular blockade other than for intubation
  5. General anesthesia in the 24 hours prior to study initiation
  6. An acquired Central Nervous System (CNS) condition (i.e. encephalitis, traumatic brain injury) resulting in ongoing dysfunction or an acquired condition resulting in ongoing dysfunction
  7. Acute hepatitis or severe liver disease
  8. Known history of sensitivity to midazolam and/or dexmedetomidine or their constituents
  9. Systolic blood pressure (SBP) below 5th percentile for two consecutive measurements
  10. Heart rate (HR) below 5th percentile for two consecutive measurements
  11. Death is deemed to be imminent or inevitable during the admission and either the intensivist or substitute decision maker is not committed to full active resuscitation
  12. Previous enrollment into the study
05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Active comparator
    Dexmedetomidine

    Drug: Precedex

  • Active comparator
    Midazolam

    Drug: Midazolam

Interventions

  • DrugDexmedetomidineStudies of DexmedetomidineDexmedetomidine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Precedex, dexmedetomidine hydrochloride, IV, 4mcg/mL, infusion duration determined by the clinical care team

    Also known as: dexmedetomidine

  • Midazolam, IV, 5mg/mL (for patients more than 10kg), 1mg/mL (for patients 2-10kg), infusion duration determined by the clinical care team

06

What researchers measure

Primary outcomes

  1. Target Sedation Range

    The percentage of time spent within target sedation range, defined as COMFORT Behaviour Scale score of 11-22, which will be assessed at minimum every 4 hours.

    Time frame: Up to 14 days post-randomization

Secondary outcomes

  1. Delirium

    Prevalence of delirium using the Cornell Assessment of Pediatric Delirium (CAPD) tool

    Time frame: Up to 14 days post-randomization

  2. Delirium

    Duration of delirium using the Cornell Assessment of Pediatric Delirium (CAPD) tool

    Time frame: Up to 14 days post-randomization

  3. Delirium

    Prevalence of delirium using raw and quantitative EEG

    Time frame: Up to 14 days post-randomization

  4. Delirium

    Duration of delirium using raw and quantitative EEG

    Time frame: Up to 14 days post-randomization

  5. Duration of mechanical ventilation

    Mechanical ventilation-free days through day 28 will be calculated as 28 minus the duration of mechanical ventilation. Participants who die, are still receiving mechanical ventilation, or are transferred from the PCCU still receiving mechanical ventilation by day 28 will be censored at 28 days and assigned zero mechanical ventilation-free days

    Time frame: Up to 28 days post-randomization

  6. PCCU Length of Stay

    Length of stay will be calculated from the time of PCCU admission to the time of PCCU discharge.

    Time frame: Up to 90 days post-randomization

  7. Hospital Length of Stay

    Hospital Length of Stay will be calculated from the time of PCCU admission to the time of physical hospital discharge.

    Time frame: Up to 90 days post-randomization

  8. Adverse event (AE) occurrence

    Documentation of treatment related adverse events including blood pressure/heart rate changes requiring decreasing or discontinuation of study drug or intervention, delirium requiring medical treatment, any unplanned extubation or line removals, aspirations, ulcerations, etc.determined to result from inadequate sedation

    Time frame: Randomization to 90 days post-randomization

  9. Quantification of sleep stages and sleep quality assessment

    Visual and automated scoring of sleep stages from EEG recordings Stage 1 sleep: scored when more than 15 seconds of the epoch is made up of theta activity (4to7 Hz) Stage 2 sleep: predominant theta activity (4 to 7 Hz) and occasional quick bursts of faster activity Stage 3/4 sleep: marked by high-amplitude slow waves Rapid eye movement (REM) sleep: characterized by low-amplitude, mixed-frequency theta waves, intermixed with some alpha waves (usually 1 to 2 Hz slower than wake).

    Time frame: Up to 14 days post-randomization

  10. Pharmacokinetics - Maximum plasma concentration (Cmax)

    Maximum plasma concentration (Cmax)

    Time frame: Up to 14 days post-randomization

  11. Pharmacokinetics - Area under the plasma concentration-time curve (AUC)

    Area under the plasma concentration-time curve (AUC)

    Time frame: Up to 14 days post-randomization

  12. Use of open label boluses for sedation - number

    Number of boluses (opioid and benzodiazepine) administered during the treatment period

    Time frame: Up to 14 days post-randomization

  13. Use of open label boluses for sedation - total dose

    Total dose of boluses (opioid and benzodiazepine) administered during the treatment period

    Time frame: Up to 14 days post-randomization

Other outcomes

  1. Economic Analysis

    The investigators will perform an economic evaluation during this pilot trial. This will be cost estimate analysis based on approximate costs incurred daily in the PCCU. Costs will be determined at discharge from estimated cost per day of admission to the PCCU.

    Time frame: Up to 90 days post-randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Sep 2024, 39 months after the start.

Of 27 phase 3 interventional studies under Delirium, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 59. This study's planned 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2019
First posted
Sep 9, 2019
StartActual
Jun 8, 2021
Primary completionEst.
Sep 2024
CompletionEst.
Sep 2024
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04082767
Lead sponsor
Douglas Fraser
Responsible party
Douglas Fraser (Paediatric Intensivist, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Sponsor-investigator
First posted
Sep 9, 2019
Start date
Jun 8, 2021
Primary completion
Sep 2024 (estimated)
Completion
Sep 2024 (estimated)
Last update
Dec 11, 2023

Study contacts

Maysaa Assaf, BSc
Contact
maysaa.assaf@lhsc.on.ca
519-685-8500 ext. 77548
Douglas D Fraser, MD., PhD
principal investigator · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dexmedetomidine · Midazolam

Start the discussion